ACADEMIA

Japan’s 1st Constipation Treatment Guidelines Recommend Drugs Acting on Epithelial Function Including Amitiza

October 25, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s first guidelines for the treatment of chronic constipation, which were published early this month, recommend the use of drugs acting on epithelial function such as Mylan EPD’s Amitiza (lubiprostone). The guidelines, drafted by a study group of the Japanese…

To read the full story

Armed with 2 New Drugs, EA Pharma Looks to Raise Profile in Chronic Constipation Space
December 12, 2018

ACADEMIA

CAR-T Reimbursement Insufficient, Kyoto University Hospital Chief Warns
March 11, 2026
Japan Begins Investigator-Led PII of Padcev in Small Bowel Adenocarcinoma
March 3, 2026
63% of OB-GYN Clinics Adopt RSV Maternal Vaccine 1 Year after Launch
February 25, 2026
Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…